Table 7.
Association of Serum Peroxiredoxin 4 With Incident Myocardial Infarction, Cerebrovascular Events, and Cardiovascular Mortality (n=8141)
| Tertiles of Peroxiredoxin 4, U/L | |||
|---|---|---|---|
| 1 | 2 | 3 | |
| Incident myocardial infarction | |||
| No. of cases, % | 51 (5.8) | 63 (7.8) | 94 (10.1) |
| Unadjusted HR (95% CI) | 1.00 | 1.04 (0.71 to 1.52) | 1.43 (1.00 to 2.06) |
| Multivariate-adjusted HR (95% CI)* | 1.00 | 0.98 (0.67 to 1.43) | 1.06 (0.74 to 1.53) |
| Incident cerebrovascular disease | |||
| No. of cases, % | 39 (6.1) | 58 (8.2) | 88 (13.3) |
| Unadjusted HR (95% CI) | 1.00 | 1.00 (0.64 to 1.55) | 1.73 (1.16 to 2.58) |
| Multivariate-adjusted HR (95% CI)* | 1.00 | 0.93 (0.60 to 1.45) | 1.28 (0.85 to 1.91) |
| Incident cardiovascular mortality | |||
| No. of cases, % | 28 (1.0) | 44 (5.9) | 63 (9.1) |
| Unadjusted HR (95% CI) | 1.00 | 1.48 (0.84 to 2.59) | 2.10 (1.23 to 3.58) |
| Multivariate-adjusted HR (95% CI)* | 1.00 | 1.35 (0.77 to 2.36) | 1.38 (0.80 to 2.36) |
*
Hazard ratios (HRs) with 95% confidence intervals (95% CIs) have been adjusted for model 2, in which the Framingham risk factors included age, sex, smoking, systolic blood pressure, use of antihypertensive therapy, diabetes at baseline, total cholesterol, and HDL cholesterol.